Navigation Links
Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
Date:6/2/2008

NEW HAVEN, Conn., June 2 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced that interim data from the pivotal Phase II trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in elderly patients with de novo poor-risk acute myelogenous leukemia (AML) had been presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO(R)) in Chicago, Illinois.

At ASCO(R), data were presented in 85 evaluable patients. The median age of these patients was 73 years (range of 60-87 years). Ninety-five percent of patients had two or more risk factors associated with a poor prognosis in elderly AML and 74% had three or more risk factors. The most common risk factors were age greater than or equal to 70 (78% of patients), and cardiac and pulmonary dysfunction (73% and 76% of patients respectively). In addition, 47% of patients had unfavorable cytogenetics.

The overall complete response rate was 35% (22 CR and 8 CRp). 90% of responses occurred after first induction treatment. While follow-up is still ongoing, the median (range) of overall survival for responders was 6.3 months (1.7-16.4 months) and for all patients was 3.2 months (0.1-16.4 months).

The induction death rate within 30 days of first induction treatment was 14%. The majority of first induction deaths were either due to progression of disease or infection. Myelosuppression was the primary toxicity, with pneumonia, infection and sepsis and non-infectious pulmonary disorders (hypoxia and dyspnea) being the most common severe adverse events (greater than or equal to grade 3).

Dr. Gary Schiller, Professor of Medicine at the David Geffen School of Medicine at UCLA and a lead investigator on the study, said "The
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
2. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
3. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
4. Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting
5. Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial
6. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
7. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
8. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
9. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
10. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
11. Tioga Pharmaceuticals Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... -- Stryker Corporation,s Orthopaedics Division, the Official Joint Replacement Products of ... of joint health to golf fans in its home state ... The Barclays.  The company,s fan destination – "The Stryker Mobility ... 17 th fairway at the Ridgewood Country Club in ... st .    At The Barclays, Stryker will ...
(Date:8/19/2014)... 19, 2014  SCILEX Pharmaceuticals, Inc., a company engaged ... for the treatment of pain, announced that it had formed ... Jeff Gudin , Dr. Charles Argoff , ... Vought . SCILEX Chief Executive Officer ... board would greatly assist in the development and commercialization ...
(Date:8/19/2014)... , August 19, 2014 ... ), a clinical-stage pharmaceutical company focused on the ... that the Intellectual Property Department of ... for its invention, titled "Methods and Compositions for ... Pharmaceuticals  Oramed Pharmaceuticals is a technology ...
Breaking Medicine Technology:Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 2Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 3Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 4Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 5SCILEX Pharmaceuticals Announces Scientific Advisory Board 2SCILEX Pharmaceuticals Announces Scientific Advisory Board 3SCILEX Pharmaceuticals Announces Scientific Advisory Board 4Oramed Granted Patent in Spain for Oral Administration of Insulin 2Oramed Granted Patent in Spain for Oral Administration of Insulin 3
(Date:8/20/2014)... Botanica Day Spa ... the new and popular stem cell line from ... and wrinkles and naturally repairs the skin. The ... new service by offering clients a complimentary dermaplaning ... facial. , Pevonia® continues to be a global ...
(Date:8/20/2014)... has been chosen by Plymouth University to be an ... April 2009 to raise awareness of, and funding for, ... brain tumour patients. , A range of events and ... the charity, and members of staff and students, as ... donate, fundraise and volunteer. The involvement of the wider ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 If old age ... a cure for it. With extensive research on HGH and ... ‘MetroMD’ claims to have perfected the art of rubbing off ... brand new younger look with their revolutionary anti-aging hormone therapy ... the 21st century fountain of youth, the MD of MetroMD, ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 New Jersey’s ... needs of an estimated tens of thousands of patients ... new Bill A3525—a bill that would expand the list ... their own cannabis—earlier this summer by State Assemblywoman Linda ... medicinal quality marijuana is growing. , To help fill ...
(Date:8/20/2014)... In a recent article published by ... London (UCL) study showed that dental experts from around ... teeth was the most effective. Analysis of 66 different ... were frequently recommended, but none were favored by a ... experienced cosmetic dentist Dr. Patrick J. Broome, ...
Breaking Medicine News(10 mins):Health News:New Stem Cell Facial Unveiled at Botanica Day Spa 2Health News:New Stem Cell Facial Unveiled at Botanica Day Spa 3Health News:Plymouth University chooses Brain Tumour Research as official charity 2Health News:MetroMD Offers Revolutionary Anti-aging Hormone Therapy in Hollywood Area 2Health News:Oaksterdam University to Host Four-Day Educational Marijuana Horticultural Seminar Aug 23-26; Training Fills Information Gap for Medical Marijuana Caregivers and Patients 2Health News:Oaksterdam University to Host Four-Day Educational Marijuana Horticultural Seminar Aug 23-26; Training Fills Information Gap for Medical Marijuana Caregivers and Patients 3Health News:Ending Confusion About the Best Way to Brush Teeth 2Health News:Ending Confusion About the Best Way to Brush Teeth 3
... Nanophase Technologies (Nasdaq: NANX ) ... products, announced today that the Company accepted the resignation ... Chief Technology Officer, so that he may pursue new ... several of the Company,s key patents and served as ...
... 3 WXYZ is proud to announce that ... Peter Nielsen , will now be seen exclusively on Channel ... than 15 years Peter Nielsen has hosted the nationally syndicated ... the author of numerous books and videos on health and fitness and ...
... the day has surprising impact on young people GAITHERSBURG, ... the importance of breakfast for students, Sodexo, a leading ... 470 school districts across the country, has created a ... time for National School Breakfast Week, March 2-6."Studies repeatedly ...
... to Improve, Automate Health Care in Master-Planned CommunitiesSCOTTSDALE, Ariz., ... of acres across the West but it,s his company,s ... would radically alter the use of energy grids. ... that message this week to The Wall Street Journal,s ...
... Exhibit www.donaldverger.com PORTLAND, Maine, March 3 A ... jail over a period of three days at ... the charges were dismissed, Verger was compelled to ... http://www.newscom.com/cgi-bin/prnh/20090303/NE78221 )"We are deeply grateful to Mr. ...
... of Pennsylvania School of Medicine and the University ... cells that spur misplaced bone growth. Unexpectedly, the ... vessels deep within skeletal muscle and other connective ... work also shows that cells important in the ...
Cached Medicine News:Health News:Nanophase Announces Changes in Principal Officers and Directors 2Health News:Nanophase Announces Changes in Principal Officers and Directors 3Health News:Peter Nielsen Has a New Home on WXYZ-TV! 2Health News:Sodexo Shares Top Breakfast Benefits for Students 2Health News:Innovative Plans by Major Arizona-Based Developer Sparks Landmark Energy Conservation Legislation in Multiple States to Urge Federal Action at Wall Street Journal Conference This Week with Gore, Google CEO & T. Boone Pickens 2Health News:Award Winning Photographer and Museum Founder to Donate Iconic Images In Support of the Innocence Project 2Health News:Award Winning Photographer and Museum Founder to Donate Iconic Images In Support of the Innocence Project 3Health News:Award Winning Photographer and Museum Founder to Donate Iconic Images In Support of the Innocence Project 4Health News:Misplaced metamorphosis 2
... innovative B-Twin Expandable Spinal System is intended ... The Implant - preloaded on its Delivery ... intervertebral space in a reduced configuration of ... up to 15mm (depending on the size ...
... on the Alpha 5 include a newly ... digital processor specifically designed for ultrasonic signals. ... reduces image speckle and enables clearer imaging ... The enhanced user confidence afforded by Alpha ...
... NCP-2, ACS proudly introduces full disclosure to ... tools for assessing the administration of ECP ... ECP Treatment Report.,The ACS Treatment Report is ... both physicians and therapists to review patient ...
... monitors and controls patient temperature primarily in ... surgery, trauma, or other medical conditions. The ... provided from a patient temperature probe. Circulating ... and 42C (107.6F) to achieve a preset ...
Medicine Products: